Guangdong Hybribio Biotech Unit Gets China Nod for HPV Diagnostic Kit
China's medical products administrator approved Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou Kaipu Pharmaceutical Technology's medical device registration for its SOX1 and PAX1 gene methylation detection kit.
The kits are used to diagnose 12 high-risk human papillomavirus (HPV) genotypes in females, according to a Wednesday filing with the Shenzhen Stock Exchange.
The permit is valid for five years.
Price (RMB): ¥5.28, Change: ¥+0.020, Percent Change: +0.38%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。